Nature Reviews Urology · Nov 18, 2026

The case for preventive prostatectomy in patients with a high risk of malignancy

By Czarnogórski MC, Tomczak W, Koper K et al.

A growing body of evidence has highlighted the importance of hereditary factors in determining a man's risk of prostate cancer. Germline mutations, such as those in BRCA genes, increase lifetime risk and contribute to more aggressive disease. As our understanding of these risks has increased, surgical techniques for prostate removal, particularly robot-assisted radical prostatectomy (RARP), have been refined, enabling precise nerve-sparing and excellent functional outcomes. These refinements, combined with increased availability of genetic testing and improved genetic counselling, mean that risk-eliminating, function-sparing prostatectomy could be a realistic management approach for carefully selected, well-informed, consenting individuals definitively identified as being at high risk of significant, aggressive prostate cancer and with additional clinical risk factors, including persistently rising PSA, elevated PSA density (≥0.15), suspicious lesions on mpMRI (PI-RADS ≥3), or abnormal digital rectal examination (DRE). Endoconfocal microscopy and NeuroSAFE RARP protocols might further improve nerve sparing and functional outcomes, increasing the feasibility of preventive surgery. Beyond the oncological implications of a potentially aggressive future tumour, psychological distress among men carrying high-risk mutations can be profound, and definitive surgical prevention could provide relief for patients whose mutation status causes substantial anxiety. Risk-eliminating prostatectomy requires consideration of scientific, surgical, psychological, ethical and legal factors. Implementing such programmes requires precise candidate selection and an understanding of the risks and controversies surrounding prophylactic surgery, as well as alternatives including focal therapy and active surveillance. Responsible exploration of this potential next frontier in hereditary prostate cancer prevention requires substantial further research and a framework to ensure that studies are ethical and clinically useful.

doi.org/10.1038/s41585-026-01213-zPubMed 43052368Interventions

AgingResearch.News